Onkológia S3/2022

Prolonged remission of recurrently relapsing immune thrombocytopenia after treatment with eltrombopag

Introduction: Immune thrombocytopenia (ITP) is immunologically conditional disease characterized by isolated thrombocytopenia, while no other known cause of thrombocytopenia is present. ITP is manifested by mainly mucosal and cutaneous hemorrhage, especially alongside reduction of thrombocytes levels below 20-30x109/l. The aim of the therapy is not reaching standardization of thrombocyte numbers, but securing hemorrhage control and preventing consequent bleeding episodes and thus increasing the quality of lives of patients with this life-threatening disease. The case: In the article, we present the case study of a patient with repeatedly relapsing immune thrombocytopenia, in whom a one-year therapy with eltrombopag resulted in long-term remission of the disease. Despite having to repeatedly modify dosing of the drug due to fluctuating values of thrombocytes, we did not see a single case of bleeding complications and eventually we were able to finish the therapy. Conclusion: Our practical experience refers to good clinical effect of ITP treatment with eltrombopag keeping the remission of the disease even after finishing the therapy. Thus, we confirm the literary data concerning the possibility of persisting remission after the end of treatment with eltrombopag in part of patients with ITP.

Keywords: imunne trombocytopenia, splenectomy, relaps, eltrombopag, phlebothrombosis, remission